Top

Published in:

01-06-2018 | Original Article

Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

Authors: Ugur Sahin, Klara Dalva, Funda Gungor, Celalettin Ustun, Meral Beksac

Published in: Annals of Hematology | Issue 6/2018

Abstract

Impact of donor-recipient killer immunoglobulin-like receptor (KIR) gene-gene matching on transplant outcomes is still inconclusive. Recent data suggest that killer cell immunoglobulin-like receptor (KIR) regulated natural killer cell (NK cell) activity may contribute to graft versus leukemia (GvL) effects and graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This case-control study aims to evaluate the effects of both aKIR and iKIR donor-recipient genotype matching on the outcomes of T cell replete HLA-identical sibling allo-HSCTs in a homogenous young patient population with myeloid leukemias. Five transplant outcomes including relapse rate (RR), disease-free survival (DFS), overall survival (OS), cumulative incidences of acute GvHD (aGvHD), and chronic GvHD (cGvHD) are investigated. Out of 96 HLA-identical sibling donor-recipient pairs, 34 were matched for activating KIR (aKIR), 38 for inhibitory KIR (iKIR), and 20 for both aKIR and iKIR. Fourty-four pairs were mismatched for both iKIR and aKIR. In univariate analysis, aKIR-matching resulted with a decrease in relapse rate (RR) (hazard ratio [HR]: 0.4; p = 0.04) and an increase in disease-free survival (DFS) (HR: 0.5; p = 0.03). In addition, cGvHD ocurred less frequently in the aKIR-matched (odds ratio [OR]: 0.4; p = 0.04) or iKIR-matched (OR: 0.3; p = 0.009) cohorts. Matching for both aKIR and iKIR was also associated with a decrease in cGvHD incidence (OR: 0.3; p = 0.02). iKIR-matching had no effects on RR, OS, or DFS. Analysis of donor haplotype effects showed haplotype-BB to have a tendency towards reduced relapse rate (HR: 0.4; p = 0.08) and better OS (HR: 0.4; p = 0.04); haplotype-Bx to increase the incidence of cGvHD (OR: 4.1; p = 0.03). In multivariate analysis, DFS advantage remained significant for aKIR-matching (HR: 0.5; p = 0.04); cGvHD incidence was reduced in the presence of iKIR-match (OR: 0.3; p = 0.02) and increased in the presence of haplotype-AB and -BB donors (OR: 7.9; p = 0.02; OR: 5.1; p = 0.03, respectively). In an attempt to investigate the pathogenesis underlying KIR-matching, we searched for residual NK/T cells on day 0 peripheral blood samples of six additional recipients and noted the presence of CD3⁺ (7.0–91.4 × 10⁶/L) and CD56⁺57⁺ (0.8–12.7 × 10⁶/L) cells. In conclusion, conditioning regimen surviving recipient NK/T cells potentially influenced by KIR-matching may contribute to GvL/GvH reactions.

Available only for authorised users

Beksac M, Dalva K (2012) Role of killer immunoglobulin-like receptor and ligand matching in donor selection. Bone Marrow Res 2012:271695–271696. https://doi.org/10.1155/2012/271695 CrossRefPubMedPubMedCentral

Passweg JR, Huard B, Tiercy JM, Roosnek E (2007) HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol 28(10):437–441. https://doi.org/10.1016/j.it.2007.07.008 CrossRefPubMed

Ljunggren HG, Karre K (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11(7):237–244CrossRefPubMed

Hsu KC, Dupont B (2005) Natural killer cell receptors: regulating innate immune responses to hematologic malignancy. Semin Hematol 42(2):91–103CrossRefPubMed

Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367(9):805–816. https://doi.org/10.1056/NEJMoa1200503 CrossRefPubMedPubMedCentral

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. https://doi.org/10.1126/science.1068440 CrossRefPubMed

Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, Nagler A, Slavin S (2004) The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63(3):204–211. https://doi.org/10.1111/j.0001-2815.2004.00182.x CrossRefPubMed

Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ (2010) Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 16(4):533–542. https://doi.org/10.1016/j.bbmt.2009.11.022 CrossRefPubMed

Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J (2012) T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 18(6):937–943. https://doi.org/10.1016/j.bbmt.2011.11.024 CrossRefPubMed

10.

Neuchel C, Furst D, Niederwieser D, Bunjes D, Tsamadou C, Wulf G, Pfreundschuh M, Wagner E, Stuhler G, Einsele H, Schrezenmeier H, Mytilineos J (2017) Impact of donor activating KIR genes on HSCT outcome in C1-ligand negative myeloid disease patients transplanted with unrelated donors-a retrospective study. PLoS One 12(1):e0169512. https://doi.org/10.1371/journal.pone.0169512 CrossRefPubMedPubMedCentral

11.

Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, Pohlman B, Andresen S, Theil KS, Dean R, Bolwell BJ (2007) Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 39(7):417–424. https://doi.org/10.1038/sj.bmt.1705609 CrossRefPubMed

12.

Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102(3):814–819. https://doi.org/10.1182/blood-2003-01-0091 CrossRefPubMed

13.

Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100(10):3825–3827. https://doi.org/10.1182/blood-2002-04-1197 CrossRefPubMed

14.

Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, Grosse-Wilde H (2005) Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105(6):2594–2600. https://doi.org/10.1182/blood-2004-04-1441 CrossRefPubMed

15.

De Santis D, Bishara A, Witt CS, Nagler A, Brautbar C, Slavin S, Christiansen FT (2005) Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 65(6):519–528. https://doi.org/10.1111/j.1399-0039.2005.00396.x CrossRefPubMed

16.

Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM, Kir Study Group CfIB, Marrow Transplantation R (2006) The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12(8):876–884. https://doi.org/10.1016/j.bbmt.2006.05.007 CrossRefPubMed

17.

Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, DeFor T, Verneris MR, Blazar BR, Miller JS (2009) Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 113(22):5628–5634. https://doi.org/10.1182/blood-2008-12-197467 CrossRefPubMedPubMedCentral

18.

Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, Kogler G, Beguin Y, Navarrete C, Devos T, Ionescu I, Boudjedir K, Herr AL, Gluckman E, Rocha V (2009) KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 23(3):492–500. https://doi.org/10.1038/leu.2008.365 CrossRefPubMed

19.

Bjorklund AT, Schaffer M, Fauriat C, Ringden O, Remberger M, Hammarstedt C, Barrett AJ, Ljungman P, Ljunggren HG, Malmberg KJ (2010) NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 115(13):2686–2694. https://doi.org/10.1182/blood-2009-07-229740 CrossRefPubMedPubMedCentral

20.

Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC (2004) The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103(4):1521–1526. https://doi.org/10.1182/blood-2003-02-0438 CrossRefPubMed

21.

Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105(12):4878–4884. https://doi.org/10.1182/blood-2004-12-4825 CrossRefPubMedPubMedCentral

22.

McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P (2007) Donor-recipient combinations of group a and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68(5):309–323. https://doi.org/10.1016/j.humimm.2007.01.019 CrossRefPubMedPubMedCentral

23.

Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, Barrett AJ (2010) Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 16(9):1257–1264. https://doi.org/10.1016/j.bbmt.2010.03.004 CrossRefPubMedPubMedCentral

24.

Wang H, He Y, Zhai WJ, Wang M, Zhou Z, Zhao YX, Feng SZ, Han MZ (2013) The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies. Swiss Med Wkly 143:w13717. https://doi.org/10.4414/smw.2013.13717 PubMed

25.

Verheyden S, Schots R, Duquet W, Demanet C (2005) A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19(8):1446–1451. https://doi.org/10.1038/sj.leu.2403839 CrossRefPubMed

26.

Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Masood Khan F (2016) Donor-recipient matching for KIR genotypes reduces chronic GVHD and missing inhibitory KIR ligands protect against relapse after Myeloablative, HLA matched hematopoietic cell transplantation. PLoS One 11(6):e0158242. https://doi.org/10.1371/journal.pone.0158242 CrossRefPubMedPubMedCentral

27.

Farag SS (2016) Killer cell immunoglobulin-like receptor ligand mismatching: to match or mismatch? Biol Blood Marrow Transplant 22(2):192–194. https://doi.org/10.1016/j.bbmt.2015.11.1101 CrossRefPubMed

28.

Yahng SA, Jeon YW, Yoon JH, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim HJ (2016) Negative impact of unidirectional host-versus-graft killer cell immunoglobulin-like receptor ligand mismatch on transplantation outcomes after Unmanipulated Haploidentical peripheral blood stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 22(2):316–323. https://doi.org/10.1016/j.bbmt.2015.09.018 CrossRefPubMed

29.

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15(3):367–369. https://doi.org/10.1016/j.bbmt.2008.12.497 CrossRefPubMedPubMedCentral

30.

Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Socie G, Societe Francaise de Greffe de Moelle et Therapie C, Dana Farber Cancer I, International Bone Marrow Transplant R (2005) Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber cancer institute (DFCI), and international bone marrow transplant registry (IBMTR) prospective study. Blood 106(4):1495–1500. https://doi.org/10.1182/blood-2004-11-4557 CrossRefPubMedPubMedCentral

31.

Fraser CJ, Scott Baker K (2007) The management and outcome of chronic graft-versus-host disease. Br J Haematol 138(2):131–145. https://doi.org/10.1111/j.1365-2141.2007.06652.x CrossRefPubMed

32.

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956. https://doi.org/10.1016/j.bbmt.2005.09.004 CrossRefPubMed

33.

Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5(3):201–214. https://doi.org/10.1038/nri1570 CrossRefPubMed

34.

Dorak MT (2007) Role of natural killer cells and killer immunoglobulin-like receptor polymorphisms: association of HLA and KIRs. Methods Mol Med 134:123–144CrossRefPubMed

35.

Hsu KC, Chida S, Geraghty DE, Dupont B (2002) The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190:40–52CrossRefPubMed

36.

European Bioinformatics Institute (2016) Donor KIR B-content group calculator. http://www.ebi.ac.uk/ipd/kir/donor_b_content.html

37.

Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116(14):2411–2419. https://doi.org/10.1182/blood-2010-05-283051 CrossRefPubMedPubMedCentral

38.

Bursac Z, Gauss CH, Williams DK, Hosmer DW (2008) Purposeful selection of variables in logistic regression. Source Code Biol Med 3:17. https://doi.org/10.1186/1751-0473-3-17 CrossRefPubMedPubMedCentral

39.

Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94(1):333–339PubMed

40.

Rocha V, Ruggeri A, Spellman S, Wang T, Sobecks R, Locatelli F, Askar M, Michel G, Arcese W, Iori AP, Purtill D, Danby R, Sanz GF, Gluckman E, Eapen M, Eurocord, Cord Blood Committee Cellular Therapy Immunobiology Working Party of the European Group for Blood and Marrow Transplantation, Netcord, and the Center for International Blood and Marrow Transplant Research (2016) Killer cell immunoglobulin-like receptor-ligand matching and outcomes after unrelated cord blood transplantation in acute myeloid leukemia. Biol Blood Marrow Transplant 22(7):1284–1289. https://doi.org/10.1016/j.bbmt.2016.04.007 CrossRefPubMedPubMedCentral

41.

Beksac K, Beksac M, Dalva K, Karaagaoglu E, Tirnaksiz MB (2015) Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival. PLoS One 10(7):e0132526

42.

Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A, Gauthier L, Romagne F, Ferracci G, Arosa FA, Moretta A, Sun PD, Ugolini S, Vivier E (2005) Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 102(37):13224–13229. https://doi.org/10.1073/pnas.0503594102 CrossRefPubMedPubMedCentral

43.

Shah N (2015) Activating KIR: iN Kase of KIR-ligand mismatch. Blood 125(20):3045–3046. https://doi.org/10.1182/blood-2015-03-634733 CrossRefPubMed

44.

Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, Jing S, Gu B, Xu Y, Sun A, He J, Wu D (2015) KIR2DS4 and its variant KIR1D are associated with acute graft-versus-host disease, cytomegalovirus, and overall survival after sibling-related HLA-matched transplantation in patients with donors with KIR gene haplotype a. Biol Blood Marrow Transplant 22(2):220–225. https://doi.org/10.1016/j.bbmt.2015.10.004 CrossRefPubMed

45.

Middleton D, Gonzalez-Galarza F, Meenagh A, Gourraud PA (2010) Diversity of KIR genes, alleles and haplotypes. In: Zimmer J (ed) Natural Killer Cells. Springer Verlag, Berlin Heidelberg, pp 63–91. https://doi.org/10.1007/978-3-642-02309-5_3 CrossRef

46.

Elmaagacli AH, Ottinger H, Koldehoff M, Peceny R, Steckel NK, Trenschel R, Biersack H, Grosse-Wilde H, Beelen DW (2005) Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 79(12):1741–1747CrossRefPubMed

47.

Bachanova V, Weisdorf DJ, Wang T, Marsh SG, Trachtenberg E, Haagenson MD, Spellman SR, Ladner M, Guethlein LA, Parham P, Miller JS, Cooley SA (2016) Donor KIR B genotype improves progression-free survival of non-Hodgkin lymphoma patients receiving unrelated donor transplantation. Biol Blood Marrow Transplant 22(9):1602–1607. https://doi.org/10.1016/j.bbmt.2016.05.016 CrossRefPubMedPubMedCentral

Title: Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation
Authors: Ugur Sahin
Klara Dalva
Funda Gungor
Celalettin Ustun
Meral Beksac
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 6/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3274-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience

Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations

An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)

Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma

Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG

Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page